Table 1 The protein expression of RPL22L1 in glioma tissue microarray.

From: RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma

Tissues

All cases

RPL22L1 expression -low (0–1 levels)

RPL22L1 expression- high (2–3 levels)

Normal

6

6 (100.0%)

0 (0.0%)

Glioma

179

64 (35.8%)

115 (64.2%)

GBM

91

24 (26.4%)

67 (73.6%)

Back to article page